A patent review of MALT1 inhibitors (2013-present)
- 15 July 2021
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 31 (12) , 1079-1096
Abstract
MALT1 is the only human paracaspase, a protease with unique cleavage activity and substrate specificity. As a key regulator of immune responses, MALT1 has attracted attention as an immune modulator...Keywords
Funding Information
- Helmholtz Zentrum München
This publication has 86 references indexed in Scilit:
- Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCLCancer Cell, 2012
- Structural Determinants of MALT1 Protease ActivityJournal of Molecular Biology, 2012
- Mechanism and specificity of the human paracaspase MALT1Biochemical Journal, 2012
- Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell linesProceedings of the National Academy of Sciences, 2011
- T‐cell receptor‐induced JNK activation requires proteolytic inactivation of CYLD by MALT1The EMBO Journal, 2011
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphomaProceedings of the National Academy of Sciences, 2009
- Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cellsJournal of Experimental Medicine, 2009
- Malt1 ubiquitination triggers NF‐κB signaling upon T‐cell activationThe EMBO Journal, 2007
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006